Critical Survey: SARTORIUS (OTCMKTS:SARTF) & CVRx (NASDAQ:CVRX)

SARTORIUS (OTCMKTS:SARTF) and CVRx (NASDAQ:CVRX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Risk & Volatility

SARTORIUS has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares SARTORIUS and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SARTORIUS	3.00%	7.79%	2.98%
CVRx	-95.61%	-79.31%	-40.96%

Institutional & Insider Ownership

75.3% of CVRx shares are held by institutional investors. 13.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for SARTORIUS and CVRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SARTORIUS	0	1	0	3	3.50
CVRx	1	0	5	1	2.86

CVRx has a consensus target price of $14.00, suggesting a potential upside of 79.49%. Given CVRx’s higher possible upside, analysts plainly believe CVRx is more favorable than SARTORIUS.

Valuation and Earnings

This table compares SARTORIUS and CVRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SARTORIUS	$3.66 billion	N/A	$90.90 million	$1.64	114.55
CVRx	$51.29 million	3.98	-$59.97 million	($2.10)	-3.71

SARTORIUS has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than SARTORIUS, indicating that it is currently the more affordable of the two stocks.

Summary

SARTORIUS beats CVRx on 9 of the 14 factors compared between the two stocks.

About SARTORIUS

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.